Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
145 hedge funds and large institutions have $1B invested in Insys Therapeutics, Inc. in 2015 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 61 increasing their positions, 50 reducing their positions, and 24 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 50
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 24
1% less funds holding
Funds holding: 146 → 145 (-1)
9% less capital invested
Capital invested by funds: $1.1B → $1B (-$94.8M)
57% less call options, than puts
Call options by funds: $32M | Put options by funds: $73.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$53.7M |
| 2 |
SCM
Scopia Capital Management
New York
|
+$31.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$28.2M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$25.6M |
| 5 |
Goldman Sachs
New York
|
+$23.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BTP
Bloom Tree Partners
New York
|
-$25.3M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$12.5M |
| 3 |
PP
PDT Partners
New York
|
-$8.75M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$7.27M |
| 5 |
Two Sigma Investments
New York
|
-$6.86M |
INSY Hedge Fund Activity: Q3 2015 in Review
145 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q3 2015, worth a combined $1B — down 8.6% from $1.1B a quarter earlier.
Fund positioning in INSY was balanced in Q3 2015: 24 funds opened new positions, 24 closed out, 61 added to existing stakes and 50 trimmed.
The largest buyer was OrbiMed, adding an estimated $53.7M. The largest seller was Bloom Tree Partners, exiting entirely with an estimated $25.3M sold.
- 145 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q3 2015, down from 146 in Q2 2015.
- Funds reported $1B of Insys Therapeutics, Inc. stock for Q3 2015, down 8.6% quarter-over-quarter.
- 24 funds opened new Insys Therapeutics, Inc. positions in Q3 2015 and 24 closed out, a net change of 0 holders.
- The largest Insys Therapeutics, Inc. buyer in Q3 2015 was OrbiMed, an estimated $53.7M added.
- The largest Insys Therapeutics, Inc. seller in Q3 2015 was Bloom Tree Partners, an estimated $25.3M sold.
Based on aggregated 13F filings for Q3 2015.